Actively Recruiting
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
Led by Hunan Province Tumor Hospital · Updated on 2024-06-04
120
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer
CONDITIONS
Official Title
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand and agree to the clinical trial requirements by signing informed consent
- Age 18 years or older
- Confirmed locally advanced or metastatic non-small cell lung cancer without prior systemic treatment
- MET exon 14 skipping confirmed by an accredited laboratory
- ECOG performance status of 0 or 1
- Predicted survival of at least 12 weeks
- Adequate bone marrow and organ function
- Presence of measurable lesions based on RECIST 1.1 criteria
- Stable brain metastases allowed
You will not qualify if you...
- Received prior systemic therapy for locally advanced or metastatic disease
- Treatment with EGFR or VEGFR antibodies within 4 weeks before starting study drug
- Radiation therapy within 14 days prior to first dose or unresolved radiation toxicity
- Use of strong CYP1A2, CYP3A inhibitors or inducers within 1-2 weeks before first dose
- Presence of spinal cord compression or meningeal metastasis
- History of other cancers within past 2 years
- Severe adverse events from prior treatments greater than grade 1 (except hair loss)
- Stroke or brain hemorrhage within 6 months prior to first dose
- Severe or uncontrolled systemic diseases including hypertension and active bleeding
- Persistent or active infections including hepatitis B, hepatitis C, HIV, or COVID-19
- Heart diseases or abnormalities
- History of interstitial lung disease or related lung conditions requiring steroids
- Severe nausea, vomiting, gastrointestinal diseases, swallowing problems, or absorption issues
- Live vaccine administration within 2 weeks before first medication
- Pregnant or breastfeeding women
- Allergy to study drugs or their components
- Other conditions deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yongchang Zhang
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
Y
Yongchang Zhang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here